Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARO-DIMERPA · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARO-DIMERPA | EXPERIMENTAL | ARO-DIMERPA in single or multiple ascending doses |
| Placebo | PLACEBO_COMPARATOR | Placebo (normal saline, 0.9%) in single or multiple matching doses |
| Name | Type | Description |
|---|---|---|
| ARO-DIMERPA | DRUG | Subcutaneous (SC) injection |
| Placebo | DRUG | Calculated volume to match active treatment by SC injection |
Inclusion Criteria: * Willing to follow diet counseling as per Investigator judgment based on local standard of care * Specific fasting TG, LDL-C, and non-high density lipoprotein cholesterol levels at Screening * Participants of childbearing potential must agree to use highly effective contracepti...
ARO-DIMERPA is an investigational small molecule being developed for the treatment of mixed hyperlipidemia, a condition characterized by elevated levels of lipids in the blood. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
ARO-DIMERPA is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ARWR. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy.
ARO-DIMERPA is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety, tolerability, and pharmacokinetics.
ARO-DIMERPA is being evaluated in a Phase 1 clinical trial registered as NCT07223658. This randomized, double-blind, placebo-controlled study is recruiting approximately 78 adult participants with mixed hyperlipidemia across Australia, Canada, Georgia, and New Zealand. The trial is currently in the recruiting stage.
No alternative names for ARO-DIMERPA have been disclosed. It is a distinct investigational compound developed by Arrowhead Pharmaceuticals. As of now, it is only known by its code name ARO-DIMERPA and is not marketed under any other brand name.